PRLD

Quote

Short

News

Articles

Message Board

Prelude Therapeutics Incorporated (NASDAQ : PRLD ) News

News Releases

PRLD News Releases

June 10, 2026 02:42:16 pm

SeekingAlpha

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

May 12, 2026 07:34:14 am

SeekingAlpha

Prelude Therapeutics GAAP EPS of -$0.13 beats by $0.12, revenue of $4.58M

May 12, 2026 07:01:00 am

GlobeNewswire

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

April 20, 2026 06:38:52 am

SeekingAlpha

Prelude Therapeutics prices $90M equity offering

April 20, 2026 06:30:00 am

GlobeNewswire

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

April 20, 2026 06:00:00 am

GlobeNewswire

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

April 15, 2026 07:30:00 am

GlobeNewswire

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

March 17, 2026 04:31:00 pm

GlobeNewswire

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

March 10, 2026 07:30:52 am

SeekingAlpha

Prelude Therapeutics GAAP EPS of -$1.29 misses by $0.04, revenue of $12.14M

March 10, 2026 07:01:00 am

GlobeNewswire

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Schedule a 30 minute Brand Awareness meeting with Market Wire News

Link Market Wire News to Your X Account